Oscar Health, Inc. (OSCR)
| Market Cap | 4.67B |
| Revenue (ttm) | 10.73B |
| Net Income (ttm) | -161.23M |
| Shares Out | 258.24M |
| EPS (ttm) | -0.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,372,441 |
| Open | 18.07 |
| Previous Close | 17.77 |
| Day's Range | 17.65 - 18.24 |
| 52-Week Range | 11.20 - 23.79 |
| Beta | 1.87 |
| Analysts | Sell |
| Price Target | 12.07 (-33.2%) |
| Earnings Date | Nov 6, 2025 |
About OSCR
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OSCR stock is "Sell." The 12-month stock price target is $12.07, which is a decrease of -33.20% from the latest price.
News
Oscar Health: The Market Is Mispricing This Disruptor
Oscar Health stock is up 21% since my strong buy rating, outperforming the S&P 500's 4% return. Membership surpassed 2.0 million in June 2025, growing 28% year-over-year compared to just 13% ACA marke...
What's Going On With Oscar Health Stock On Tuesday?
Healthcare tech firm Oscar Health Inc. OSCR priced its offering of $355 million of 2.25% convertible senior subordinated notes due 2030 in a private offering.
Oscar Health Prices Upsized $355,000,000 Convertible Senior Subordinated Notes Offering to Scale Long-Term Growth and Consumer and Employer Adoption of the Individual Market
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar”) (NYSE: OSCR) today announced the pricing of its offering of $355,000,000 aggregate principal amount of 2.25% convertible senior subordinated not...
Oscar Health Launches Proposed Convertible Senior Subordinated Notes Offering to Scale Long-Term Growth and Consumer and Employer Adoption of the Individual Market
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar”) (NYSE: OSCR) today announced its intention to offer, subject to market and other conditions, $350,000,000 aggregate principal amount of converti...
Oscar Health: The Industry Is Having A Cold But 2026 Looks To Be Much Better
Oscar Health is poised for a strong rebound in 2026 after a challenging 2025, driven by significant premium rate increases and improved pricing discipline. The company's technology-driven platform and...
Rocket, Oscar, Hims & Hers: Short Sellers Are Playing With Fire
Wall Street's most crowded shorts are starting to look like powder kegs. Rocket Companies Inc RKT, Oscar Health Inc OSCR, and Hims & Hers Health Inc HIMS are sitting at the top of the market's short-i...
What's Going On With Oscar Health Stock On Wednesday?
Oscar Health Inc. OSCR is trading lower on Wednesday, with no apparent news to explain the move. Year-to-date, the stock has gained roughly 15%.
Oscar Health: Undervalued, But Not Without Risk
Oscar Health is deeply undervalued but faces high short-term uncertainty due to ACA-specific risks and sector-wide negative catalysts. The expiration of ACA subsidies, adverse selection, and new legis...
Oscar Could Stem The Healthcare Tide
Health insurers are experiencing sharp declines in stock prices, which are likely bottoming out. Despite the downturn, it is worth bottom fishing for quality companies like Oscar Healthcare. Oscar Hea...
Hy-Vee Health and Oscar Serve Up a New Era of Employer Healthcare
NEW YORK & DES MOINES, Iowa--(BUSINESS WIRE)--Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company in the individual market, and Hy-Vee, Inc., America's No. 1 grocery store based i...
Wall Street Got Oscar All Wrong
Oscar's Q2 revenue rose 29% YoY to $2.86 billion, with membership growing 28% to over 2 million. The reported 91.1% MLR was distorted by a $692 million retroactive risk adjustment; normalized MLR was ...
Oscar Health, Inc. (OSCR) Q2 2025 Earnings Call Transcript
Oscar Health, Inc. (NYSE:OSCR) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury & Investor Relations Mark Thomas Bertolini -...
Obamacare Insurer Oscar Health, Hit By Higher Costs, Sees 2026 Rebound
Oscar Health Wednesday reported a $228 million second quarter loss but sees profits returning next year as the health insurance industry navigates an influx of sicker-than-expected patients.
Oscar Health Announces Financial Results for Second Quarter 2025 and Reaffirms Updated 2025 Guidance
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR) announced today its financial results for the second quarter ended June 30, 2025, and reaffirmed its updated full ...
Oscar Health: Underrated Growth Story With Big-Cap Ambitions
Oscar Health is facing short-term ACA market concerns and negative analyst sentiment. I think it will be short-lived. The company is expanding into the high-potential ICHRA market, leveraging operatio...
Oscar Health Ahead Of Q2: Brace For Strategic Reset
Oscar Health's online, individual-focus model has reached scale, but profitability now faces headwinds from higher medical loss ratios and policy uncertainty. Recent guidance revision signals increase...
Oscar Health Announces Preliminary Financial Results for Second Quarter 2025 and Revises 2025 Guidance
NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, announced today certain preliminary financial results for the second qua...
Oscar Health: Barclays, UBS, And Wells Fargo Downgraded, But The Real Story Says Buy
I rate Oscar Health as a buy, viewing short-term regulatory headwinds as a buying opportunity given its long-term growth prospects. Oscar's strong revenue growth, improving profitability, and efficien...
Why I'm Buying Oscar's Panic Dip
Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A ...
Oscar Health: Should You Buy OSCR Stock At $17?
On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline ...
Oscar Health: A Misunderstood Platform
Oscar generated $328.8 million in Q1 adjusted EBITDA with a 9.8% operating margin, up 110 bps year-over-year. SG&A ratio fell to 15.8%, driven by 40% fixed-cost leverage and 15% tech-driven efficienci...
Oscar Health: Building The Operating System Of American Healthcare
Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue f...
Still Cheap After Near 100% Gains? Oscar Health Stock Could Continue Higher
Oscar Health, Inc. is undervalued despite a recent rally, with strong growth and earnings potential as a tech-driven disruptor in health insurance. The company boasts accelerating revenues, improving ...
Oscar Health: I'm Bullish, But I'm Careful
Oscar Health is uniquely undervalued, combining 42% revenue growth with profitability and a low EV/Sales multiple, making it a standout in the market. The company's $2.23B cash position versus its $4....
Oscar Health Could Be The Next Growth Monster With Tremendous Upside
Oscar Health is leveraging technology and AI to disrupt the health insurance industry, driving strong membership growth and improving operational efficiency. Financials are rapidly improving: premium ...